Streetbeat News

Price Targets

TAST

Stephens & Co. analyst Joshua Long maintains an Overweight rating on Carrols Restaurant Group (NASDAQ:TAST) and raises the price target from $6 to $10.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:23 am

FEMY

Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Femasys (NASDAQ:FEMY) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:22 am

RCKT

Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintained a price target of $61.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:20 am

FDMT

Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a price target of $31.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:19 am

MGTX

Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on MeiraGTx Hldgs (NASDAQ:MGTX) and maintained a price target of $41.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:18 am

CRD

Barrington Research analyst Kevin Steinke has reiterated an 'Outperform' rating on Crawford & Company Common Stock (NYSE:CRD) and maintained a $14 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:13 am

NXST

Barrington Research analyst James Goss has reiterated an 'Outperform' rating on Nexstar Media Gr (NASDAQ:NXST) and maintained a price target of $235.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:12 am

CLSK

Chardan Capital analyst Brian Dobson maintains a 'Buy' rating on Cleanspark (NASDAQ:CLSK) and raises the price target from $10 to $11.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:11 am

CYBR

Needham analyst Alex Henderson maintains a 'Buy' rating on CyberArk Software (NASDAQ:CYBR) and raises the price target from $185 to $190.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:10 am

PHAT

Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a price target of $23.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 8:09 am